




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Interventions and Coronary Artery Disease</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=2e96633a-1c99-4f33-9eda-83554d60f058</link>
        <description>Clinical Topic Feed: Interventions and Coronary Artery Disease</description>
        <language>en</language>

        

                <item>
                    <title>Beyond Calcium: CTA Plaque Characteristics in South Asian Patients in the DILWALE Registry</title>
<link>/Latest-in-Cardiology/Articles/2026/09/21/17/24/Beyond-Calcium</link>                    <description>South Asian (SA) individuals experience a disproportionate burden of premature atherosclerotic cardiovascular disease (ASCVD), and this excess risk is not fully explained by traditional risk factors.</description>
                    <pubdate>1790016900000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Celebrating One Courageous Idea That Changed CV Medicine Forever</title>
<link>/Latest-in-Cardiology/Articles/2026/09/16/18/36/Celebrating-One-Courageous-Idea-That-Changed-Cardiovascular-Medicine-Forever</link>                    <description>On Sept. 16, 1977, Andreas Gruentzig, MD, performed the first successful coronary angioplasty in Zurich, Switzerland. With a small balloon catheter, an extraordinary vision and the courage to challenge what was then considered possible, he opened a new chapter in the treatment of coronary artery disease.</description>
                    <pubdate>1789654080000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>SirPAD Redefines Drug-Coated Balloon Therapy in PAD</title>
<link>/Latest-in-Cardiology/Articles/2026/09/14/16/12/SirPAD-Redefines-Drug-Coated-Balloon-Therapy-in-PAD</link>                    <description>Peripheral artery disease (PAD) affects &amp;gt;113 million people worldwide and remains a major cause of limb loss, cardiovascular morbidity, and cardiovascular mortality.</description>
                    <pubdate>1789409820000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>CorCal Outcomes, EVAOLD, ISOLEDS Inform CV Risk Prediction, Post-MI Treatment and Stenting Strategies</title>
<link>/Latest-in-Cardiology/Articles/2026/08/29/08/48/mon-730am-corcal-evaold-isoleds-esc-2026</link>                    <description>Cardiovascular prevention, acute care and interventional cardiology converged in a wide-ranging Hot Line Session at ESC Congress 2026 that delivered new evidence on how clinicians assess risk, treat older heart attack patients and guide complex coronary procedures.</description>
                    <pubdate>1788177780000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC Journals&#226;€™ Abstracts Explore Novel Therapies, Role of Precision Medicine, and More</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-journals-esc-2026</link>                    <description>Several abstracts and e-posters presented at ESC Congress 2026 and simultaneously published across the JACC family of journals highlight the expanding role of precision medicine, novel therapeutics, and advanced risk stratification across cardiovascular care.</description>
                    <pubdate>1788002340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC Studies at ESC Congress 2026 Examine FFRct, Plaque Volume and EAT</title>
<link>/Latest-in-Cardiology/Articles/2026/08/24/12/30/sat-jacc-studies-esc-2026</link>                    <description>Three late-breaking science studies presented during ESC Congress 2026 provide new insights into the use of coronary computed tomography angiography (CCTA) fractional flow reserve (FFRct) to guide patient selection for invasive coronary angiography (ICA), the use of automated deep learning-quantified total plaque volume (TPV) to improve prediction of first coronary events, and the relationship between epicardial adipose tissue (EAT) volume and long-term major adverse cardiac events (MACE). Each study was simultaneously published in JACC Journals.</description>
                    <pubdate>1787991780000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>FFR in Focus: New Insights on Angiography-Derived Assessment and FFR-NHPR Discordance</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/08/10/15/19/FFR-in-Focus</link>                    <description>Two studies recently published in JACC: Cardiovascular Interventions provide fresh insights into coronary physiology, suggesting that angiography-derived fractional flow reserve (FFR) may be a practical alternative to wire-based FFR, while highlighting the prognostic significance of definite discordance between FFR and nonhyperemic pressure ratios (NHPR).</description>
                    <pubdate>1786468140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: ACC Updated Expert Consensus Decision Pathway on HFpEF</title>
<link>/Latest-in-Cardiology/Articles/2026/07/29/13/18/eagles-eye-view-29jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis.</description>
                    <pubdate>1785331140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>DAPT-MVD: Extended DAPT Cuts CV Events After PCI in Multivessel CAD</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/22/17/25/DAPT-MVD</link>                    <description>Extending DAPT for an additional year reduced major adverse cardiovascular events (MACE) without increasing bleeding risk compared with aspirin alone among patients with multivessel coronary artery disease (MVCAD) who had no ischemic or bleeding events one year after PCI with a drug-eluting stent, according to results of the DAPT-MVD trial published July 15 in NEJM.</description>
                    <pubdate>1784749860000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Optimizing Dual Antiplatelet Therapy in Patients With Diabetes and Multivessel Disease Undergoing PCI: The TUXEDO-2 Trial</title>
<link>/Latest-in-Cardiology/Articles/2026/06/08/10/20/Optimizing-Dual-Antiplatelet-Therapy</link>                    <description>The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2&#226;€”India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...</description>
                    <pubdate>1781024040000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>